Appendix 3B
Released
Released
Announcement PDF
20 August 2019
ASX Announcement / Media Release
Appendix 3B
20 August 2019 – Race Oncology Limited (ASX: RAC) announced earlier today the successful
completion of a $1.45 million placement, led by prominent biotechnology investor Dr Daniel
Tillett.
The attached Appendix 3B relates to the issue of the 8.5 million shares and 4.25 million
options to Dr Tillett, with the shares being issued under the Company’s 10% placement
capacity and the options under the Company’s 15% placement capacity.
The balance of the initial placement of 5 million shares and 2.25 million options able to be
issued under the Company’s remaining 15% capacity will be issued as soon as the funds have
been received.
The remainder of the placement shares and options are subject to shareholder approval.
-
ENDS
-
About Race Oncology (RAC: ASX)
Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage
drug assets in the cancer field that have been overlooked by big pharma. The company’s first asset is
Bisantrene, a chemotherapy drug, which was the subject of more than 40 clinical studies during the
1980s and 1990s before the drug was abandoned. Bisantrene has compelling Phase II data in acute
myeloid leukaemia (AML) and Race is seeking to gain US FDA approval for Bisantrene for AML under
the accelerated 505(b)(2) regulatory pathway. Bisantrene is the subject of two recently granted US
patents and a third allowed US patent. It has also been awarded US Orphan Drug designation and a
‘Rare Paediatric Disease’ (RPD) designation.
Media contact:
Heidi Cuthbert
+61 411 272 366
E: heidi.cuthbert@multiplier.com.au
Race Oncology Ltd ABN 61 149 318 749
Registered office: L40, 140 William St, Melbourne VIC 3004
www.raceoncology.com
Appendix 3B
New issue announcement
Appendix 3B
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
New issue announcement,
application for quotation of additional securities
and agreement
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13
Name of entity
RACE ONCOLOGY LIMITED
ABN
61 149 318 749
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).
1
+Class of +securities issued or to be
issued
1. Fully paid ordinary shares
2. Unlisted options
2
Number of +securities issued or to
be issued (if known) or maximum
number which may be issued
1. 8,500,000
2. 4,250,000
3
Principal terms of the +securities
(e.g. if options, exercise price and
expiry date; if partly paid
+securities, the amount outstanding
and due dates for payment; if
+convertible
securities,
the
conversion price and dates for
conversion)
1. Fully paid ordinary shares
2. Unlisted options issued on a one for two basis in
relation to the placement shares and exercisable at
$0.099 on or before 31 August 2021
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 1
4
Do the +securities rank equally in
all respects from the +issue date
with an existing +class of quoted
+securities?
1. Yes
2. Shares issued upon exercise of the unlisted
options will rank equally in all respects from the
date of issue with existing fully paid ordinary
shares.
If the additional +securities do not
rank equally, please state:
• the date from which they do
• the extent to which they
participate for the next
dividend, (in the case of a trust,
distribution) or interest payment
• the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution or interest payment
5
Issue price or consideration
1. $0.066
2. Nil
6
Purpose of the issue
(If issued as consideration for the
acquisition of assets, clearly
identify those assets)
Issued pursuant to placement announced to the market
on 20 August 2019. Funds raised are to be used for
research and development of Bisantrene and for
general working capital.
6a
Is the entity an +eligible entity that Yes
has obtained security holder
approval under rule 7.1A?
If Yes, complete sections 6b – 6h in
relation to the +securities the
subject of this Appendix 3B, and
comply with section 6i
6b
The date the security holder
resolution under rule 7.1A was
passed
27 November 2018
6c
Number of +securities issued
without security holder approval
under rule 7.1
4,250,000 unlisted options
6d
Number of +securities issued with
security holder approval under rule
7.1A
8,500,000 fully paid ordinary shares
6e
Number of +securities issued with
security holder approval under rule
7.3, or another specific security
holder approval (specify date of
meeting)
Nil
6f
Number of +securities issued under
an exception in rule 7.2
Nil
Appendix 3B
New issue announcement
6g
If +securities issued under rule
7.1A, was issue price at least 75%
of 15 day VWAP as calculated
under rule 7.1A.3? Include the
+issue date and both values.
Include the source of the VWAP
calculation.
Issue date of securities, 20 August 2019. Date price
agreed, 16 August 2019. 15 day VWAP prior to date
price agreed is $0.05992. 75% of 15 day VWAP is
$0.04494. Issue price of $0.066 represents a 10.15%
premium to the 15 day VWAP.
Source: Morningstar
6h
If +securities were issued under
rule
7.1A
for
non-cash
consideration, state date on which
valuation of consideration was
released
to
ASX
Market
Announcements
N/A
6i
Calculate the entity’s remaining
issue capacity under rule 7.1 and
rule 7.1A – complete Annexure 1
and release to ASX Market
Announcements
7.1
7.1A
7
+Issue dates
20 August 2019
7,575,371
223,581
Note: The issue date may be prescribed by ASX
(refer to the definition of issue date in rule 19.12).
For example, the issue date for a pro rata
entitlement issue must comply with the applicable
timetable in Appendix 7A.
Cross reference: item 33 of Appendix 3B.
8
Number and +class of all +securities
Number
+Class
95,735,813
Fully paid ordinary shares
Number
+Class
quoted on ASX (including the
+securities
in section 2 if
applicable)
9
Number and +class of all +securities
not quoted on ASX (including the
+securities
in section 2 if
applicable)
9,000,000
Options @ $0.25 expiring on
01/07/2021
135,000
Options @ $0.256 expiring on
01/08/2021.
1,500,000
Options @ $0.25 expiring on
01/04/2022.
100,000
Options @ $0.25 expiring on
08/05/2022.
2,000,000
Options @ $0.49 expiring on
22/11/2019
2,000,000
Options @ $0.65 expiring on
22/11/2019
5,000,000
Options @ $0.45 expiring on
19/03/2020
6,000,000
Options @ $0.30 expiring on
13/01/2020
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 3
10
Dividend policy (in the case of a
trust, distribution policy) on the
increased capital (interests)
Part 2 - Pro rata issue
11
Is security holder approval required?
12
Is the issue renounceable or nonrenounceable?
13
Ratio in which the +securities will be
offered
14
+Class
of +securities to which the
offer relates
15
+Record
date
to
determine
entitlements
16
Will holdings on different registers
(or subregisters) be aggregated for
calculating entitlements?
17
Policy for deciding entitlements in
relation to fractions
1,500,000
Options @ $0.32 expiring on
16/05/2023 with 750,000
subject to vesting conditions.
420,000
Options @ $0.12 expiring on
1/10/2023 with 70,000 subject
to vesting conditions.
2,000,000
Options @ $0.23 expiring on
27 November 2021 with
1,500,000 subject to vesting
conditions.
420,000
Options @ $0.12 expiring on
21/01/2024 with 210,000
subject to vesting conditions.
500,000
Options @ $0.10 expiring on
12/03/2024 subject to vesting
conditions.
100,000
Options @ $0.135 expiring on
31/05/2024 subject to vesting
conditions.
840,000
Options @ $0.085 expiring on
31/05/2024 with 700,000
subject to vesting conditions.
4,250,000
Options @ $0.099 expiring on
31 August 2021.
N/A
Appendix 3B
New issue announcement
18
Names of countries in which the
entity has security holders who will
not be sent new offer documents
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.
19
Closing date for receipt
acceptances or renunciations
of
20
Names of any underwriters
21
Amount of any underwriting fee or
commission
22
Names of any brokers to the issue
23
Fee or commission payable to the
broker to the issue
24
Amount of any handling fee payable
to brokers who lodge acceptances or
renunciations on behalf of security
holders
25
If the issue is contingent on security
holders’ approval, the date of the
meeting
26
Date entitlement and acceptance
form and offer documents will be
sent to persons entitled
27
If the entity has issued options, and
the terms entitle option holders to
participate on exercise, the date on
which notices will be sent to option
holders
28
Date rights trading will begin (if
applicable)
29
Date rights trading will end (if
applicable)
30
How do security holders sell their
entitlements in full through a
broker?
31
How do security holders sell part of
their entitlements through a broker
and accept for the balance?
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 5
32
33
How do security holders dispose of
their entitlements (except by sale
through a broker)?
+Issue date
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
34
(a)
Type of +securities
(tick one)
X
+Securities described in Part 1
All other +securities
(b)
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee
incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing the information or
documents
35
If the +securities are +equity securities, the names of the 20 largest holders of the
additional +securities, and the number and percentage of additional +securities held by
those holders
36
If the +securities are +equity securities, a distribution schedule of the additional
+securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
37
A copy of any trust deed for the additional +securities
Entities that have ticked box 34(b)
38
39
Number of +securities for which
+quotation is sought
+Class
of +securities for which
quotation is sought
Appendix 3B
New issue announcement
40
Do the +securities rank equally in all
respects from the +issue date with an
existing +class of quoted +securities?
If the additional +securities do not
rank equally, please state:
• the date from which they do
• the extent to which they
participate for the next dividend,
(in the case of a trust,
distribution) or interest payment
• the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution or interest payment
41
Reason for request for quotation now
Example: In the case of restricted securities, end of
restriction period
(if issued upon conversion of another
+security, clearly identify that other
+security)
42
Number and +class of all +securities
quoted on ASX (including the
+securities in clause 38)
Number
+Class
Quotation agreement
1
+Quotation of our additional +securities is in ASX’s absolute discretion.
2
We warrant the following to ASX.
quote the +securities on any conditions it decides.
ASX may
•
The issue of the +securities to be quoted complies with the law and is not for
an illegal purpose.
•
There is no reason why those +securities should not be granted +quotation.
•
An offer of the +securities for sale within 12 months after their issue will not
require disclosure under section 707(3) or section 1012C(6) of the
Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give
this warranty
•
Section 724 or section 1016E of the Corporations Act does not apply to any
applications received by us in relation to any +securities to be quoted and that
no-one has any right to return any +securities to be quoted under sections 737,
738 or 1016F of the Corporations Act at the time that we request that the
+securities be quoted.
•
If we are a trust, we warrant that no person has the right to return the
+securities to be quoted under section 1019B of the Corporations Act at the
time that we request that the +securities be quoted.
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 7
3
We will indemnify ASX to the fullest extent permitted by law in respect of any claim,
action or expense arising from or connected with any breach of the warranties in this
agreement.
4
We give ASX the information and documents required by this form. If any
information or document is not available now, we will give it to ASX before
+quotation of the +securities begins. We acknowledge that ASX is relying on the
information and documents. We warrant that they are (will be) true and complete.
Sign here:
Print name:
............................................................ Date 20 August 2019
(Company Secretary)
Peter Webse
Appendix 3B
New issue announcement
Appendix 3B – Annexure 1
Calculation of placement capacity under rule 7.1 and rule 7.1A
for eligible entities
Introduced 01/08/12 Amended 04/03/13
Part 1
Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
Insert number of fully paid +ordinary
securities on issue 12 months before the
+issue date or date of agreement to issue
77,235,813
Add the following:
•
Number of fully paid +ordinary
securities issued in that 12 month
period under an exception in rule 7.2
•
Number of fully paid +ordinary
securities issued in that 12 month
period with shareholder approval
•
Number of partly paid +ordinary
securities that became fully paid in that
12 month period
10,000,000 – Conversion of performance
shares Exception 4
Note:
• Include only ordinary securities here –
other classes of equity securities
cannot be added
• Include here (if applicable) the
securities the subject of the Appendix
3B to which this form is annexed
• It may be useful to set out issues of
securities on different dates as
separate line items
Subtract the number of fully paid
+ordinary securities cancelled during that
12 month period
-
“A”
87,235,813
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 9
Step 2: Calculate 15% of “A”
“B”
0.15
[Note: this value cannot be changed]
Multiply “A” by 0.15
13,085,371
Step 3: Calculate “C”, the amount of placement capacity under rule
7.1 that has already been used
Insert number of +equity securities issued
or agreed to be issued in that 12 month
period not counting those issued:
•
Under an exception in rule 7.2
•
Under rule 7.1A
•
With security holder approval under
rule 7.1 or rule 7.4
420,000 unlisted options 22 January 2019
840,000 unlisted options 31 May 2019
4,250,000 unlisted options 20 August 2019
Note:
• This applies to equity securities, unless
specifically excluded – not just ordinary
securities
• Include here (if applicable) the
securities the subject of the Appendix
3B to which this form is annexed
• It may be useful to set out issues of
securities on different dates as
separate line items
“C”
5,510,000
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining
placement capacity under rule 7.1
“A” x 0.15
13,085,371
Note: number must be same as shown in
Step 2
Subtract “C”
5,510,000
Note: number must be same as shown in
Step 3
Total [“A” x 0.15] – “C”
7,575,371
[Note: this is the remaining placement
capacity under rule 7.1]
Appendix 3B
New issue announcement
Part 2
Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
“A”
87,235,813
Note: number must be same as shown in
Step 1 of Part 1
Step 2: Calculate 10% of “A”
“D”
0.10
Note: this value cannot be changed
Multiply “A” by 0.10
8,723,581
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A
that has already been used
Insert number of +equity securities issued
or agreed to be issued in that 12 month
period under rule 7.1A
8,500,000 fully paid ordinary shares 20 August
2019
Notes:
• This applies to equity securities – not
just ordinary securities
• Include here – if applicable – the
securities the subject of the Appendix
3B to which this form is annexed
• Do not include equity securities issued
under rule 7.1 (they must be dealt with
in Part 1), or for which specific security
holder approval has been obtained
• It may be useful to set out issues of
securities on different dates as separate
line items
“E”
8,500,000
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement
capacity under rule 7.1A
“A” x 0.10
8,723,581
Note: number must be same as shown in
Step 2
Subtract “E”
8,500,000
Note: number must be same as shown in
Step 3
Total [“A” x 0.10] – “E”
223,581
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 11
Share your feedback
Discover